Suppr超能文献

缓激肽与仓鼠颊囊微血管通透性的变化:一氧化氮的作用

Bradykinin and changes in microvascular permeability in the hamster cheek pouch: role of nitric oxide.

作者信息

Félétou M, Bonnardel E, Canet E

机构信息

Départment de Pneumologie, Institut de Recherches Servier, Suresnes, France.

出版信息

Br J Pharmacol. 1996 Jul;118(6):1371-6. doi: 10.1111/j.1476-5381.1996.tb15547.x.

Abstract
  1. The objective of this study in the hamster cheek pouch was to investigate the role of nitric oxide in bradykinin-induced microvascular leakage. The cheek pouch microcirculatory bed of the anaesthetized hamster was directly observed under microscope and vascular leakage was evidenced by dextranfluorescein isothiocyanate (FITC-dextran) extravasation. 2. Bradykinin superfusion (but not [des-Arg9]-bradykinin up to 3 x 10(-6) M) induced an increase in microvascular permeability (log EC50: -6.5 +/- 0.4) which was exclusively located on the post-capillary venule. Plasma extravasation was blocked by intravenous pretreatment with Hoe 140, a bradykinin B2 receptor antagonist (estimated log ID50: -9.5 +/- 0.2). 3. The effects of bradykinin (3 x 10(-7) M) superfusion were partially but significantly inhibited by indomethacin (10(-5) M, P < 0.05) and abolished by pretreatment with L-nitro-arginine (L-NOARG; 10(-5) M). 4. Acetylcholine (10(-6) M, which releases endothelial nitric oxide (NO), and sodium nitroprusside (10(-6) M, a nitrovasodilator) superfusion did not induce any changes in permeability, per se. Cromakalim (10(-5) M, a potassium channel opener) superfusion induced a moderate but significant plasma extravasation. 5. The effects of bradykinin, blocked by L-NOARG pretreatment, were restored by the co-perfusion of either sodium nitroprusside or cromakalim. Conversely vasoconstriction, produced by a stable analogue of thromboxane A2 (U46619, 3 x 10(-7) M), inhibited the increase in permeability produced by bradykinin. 6. The measurement of arteriolar diameter showed that bradykinin induced a vasodilatation which was blocked by L-NOARG. L-NOARG in itself was a powerful vasoconstrictor. Sodium nitroprusside and cromakalim, in the presence of L-NOARG, were able to restore the inhibited vasodilator response to bradykinin. 7. These results suggest: (1) bradykinin-induced microvascular leakage is mediated by bradykinin B2 receptor activation; (2) the increase in permeability is due to two different independent phenomena, i.e. post-capillary venular endothelial gap formation and arteriolar vasodilatation which increases the post-capillary venular transmural pressure: (3) NO is only involved in the arteriolar dilatation component of the bradykinin-induced increase in microvascular permeability.
摘要
  1. 本研究在仓鼠颊囊的目的是探讨一氧化氮在缓激肽诱导的微血管渗漏中的作用。在显微镜下直接观察麻醉仓鼠的颊囊微循环床,并用异硫氰酸荧光素葡聚糖(FITC-葡聚糖)外渗证明血管渗漏。2. 缓激肽灌注(但高达3×10⁻⁶M的[去-精氨酸⁹]-缓激肽则无此作用)可诱导微血管通透性增加(对数EC₅₀:-6.5±0.4),且仅发生在毛细血管后微静脉。静脉内预先用缓激肽B2受体拮抗剂Hoe 140预处理可阻断血浆外渗(估计对数ID₅₀:-9.5±0.2)。3. 吲哚美辛(10⁻⁵M,P<0.05)可部分但显著抑制缓激肽(3×10⁻⁷M)灌注的作用,而L-硝基精氨酸(L-NOARG;10⁻⁵M)预处理可消除该作用。4. 乙酰胆碱(10⁻⁶M,可释放内皮一氧化氮(NO))和硝普钠(10⁻⁶M,一种硝基血管扩张剂)灌注本身不会引起通透性的任何变化。克罗卡林(10⁻⁵M,一种钾通道开放剂)灌注可诱导中度但显著的血浆外渗。5. L-NOARG预处理阻断的缓激肽作用可通过硝普钠或克罗卡林的共同灌注恢复。相反,血栓素A2的稳定类似物(U46619,3×10⁻⁷M)产生的血管收缩抑制了缓激肽引起的通透性增加。6. 小动脉直径的测量表明,缓激肽可诱导血管舒张,而L-NOARG可阻断该作用。L-NOARG本身是一种强大的血管收缩剂。在存在L-NOARG的情况下,硝普钠和克罗卡林能够恢复对缓激肽被抑制的血管舒张反应。7. 这些结果表明:(1)缓激肽诱导的微血管渗漏是由缓激肽B2受体激活介导的;(2)通透性增加是由于两种不同的独立现象,即毛细血管后微静脉内皮间隙形成和小动脉血管舒张,后者增加了毛细血管后微静脉的跨壁压力;(3)NO仅参与缓激肽诱导的微血管通透性增加中的小动脉舒张成分。

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验